Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV)
Clinical Infectious Diseases · 12.04.2024
DOI: 10.1093/cid/ciae189 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 12.04.2024. Verfasst von José Damas und 17 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Service, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Alanine, Anti-HIV Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SHCS, Swiss National Science Foundation.
Abstract (Originalsprache)
Background
Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF discontinuation. We evaluated weight and metabolic changes 12 months after TAF discontinuation in the Swiss HIV Cohort Study.
Methods
We included participants who received at least 6 months of TAF-containing ART between January 2016 and March 2023. Using multivariable mixed-effect models, changes in weight and lipid levels were compared between individuals who continued TAF and those who switched to one of the following TAF-free regimens: (1) tenofovir disoproxil fumarate (TDF)-based ART, (2) dolutegravir/lamivudine (DTG/3TC), or (3) long-acting cabotegravir/rilpivirine (CAB/RPV).
Results
Of 6555 participants (median age 54 years, 24.3% female, 13% Black), 5485 (83.7%) continued, and 1070 (16.3%) stopped TAF. Overall, discontinuing TAF was associated with an adjusted mean weight change of −0.54 kg (95% confidence interval [CI] −.98 to −.11) after 12 months. In stratified analyses, switching from TAF to TDF led to an adjusted mean weight decrease of −1.84 kg (95% CI −2.72 to −.97), and to a decrease in mean total cholesterol (−0.44 mmol/L) and triglycerides (−0.38 mmol/L) after 12 months. Switching from TAF-based ART to DTG/3TC (−0.17 kg, 95% CI −.82 to .48) or long-acting CAB/RPV (−0.64 kg, 95% CI −2.16 to .89) did not lead to reductions in weight.
Conclusions
Replacing TAF with TDF in PWH led to a decrease in body weight and an improved lipid profile within 1 year. Weight changes were not observed among individuals who switched to DTG/3TC or long-acting CAB/RPV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Service, University Hospital Lausanne, University of Lausanne, Lausanne, Switzerland.
- School of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
- Biomedical Data Science Center, University Hospital and University of Lausanne, Lausanne, Switzerland.
- Chair of the Positive Council, Zurich, Switzerland.
- Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University Basel, Basel, Switzerland.
- Service of Clinical Pharmacology, University Hospital Lausanne, Lausanne, Switzerland.
ORCID-Profile: José Damas, Aline Munting, Jacques Fellay, Catia Marzolini, Philip E Tarr, Dominique L Braun, Enos Bernasconi, Katharine E A Darling, Charles Béguelin, Gilles Wandeler, Matthias Cavassini, Bernard Surial
Förderung
- SHCS
- Swiss National Science Foundation
Zitieren
APA
Damas, J., Munting, A., Fellay, J., Haerry, D., Marzolini, C., Tarr, P. E., Steffen, A., Braun, D. L., Stoeckle, M., Bernasconi, E., Nawej Tshikung, O., Fux, C. A., Darling, K. E. A., Béguelin, C., Wandeler, G., Cavassini, M., Surial, B., & Swiss HIV Cohort Study (SHCS) (2024). Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae189
Vancouver
Damas J, Munting A, Fellay J, Haerry D, Marzolini C, Tarr PE, et al. Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae189
BibTeX
@article{Damas2024,
author = {Damas, José and Munting, Aline and Fellay, Jacques and Haerry, David and Marzolini, Catia and Tarr, Philip E and Steffen, Ana and Braun, Dominique L and Stoeckle, Marcel and Bernasconi, Enos and Nawej Tshikung, Olivier and Fux, Christoph A and Darling, Katharine E A and Béguelin, Charles and Wandeler, Gilles and Cavassini, Matthias and Surial, Bernard and Swiss HIV Cohort Study (SHCS), Swiss HIV Cohort Study (SHCS)},
title = {Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide (TAF) in People With Human Immunodeficiency Virus (HIV)},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae189}
}
EUVIMED